Dr. Andrea Apolo On Avelumab and its Effect on Locally Advanced or Metastatic Urothelial Carcinoma
Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.
Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.
The anti-PD-L1 antibody avelumab has shown promising results in refractory, metastatic urothelial carcinoma. The checkpoint inhibitor had clinical activity, showing tumor shrinkage, says Apollo. There is no data yet regarding overall survival, but durable responses have been observed. This development is exciting for bladder cancer research, Apolo adds.
Next steps in the research include studying the agent in large clinical trials. These studies include identifying biomarkers and investigating potential combination therapies, Apolo says.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
